Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia

Clinical trial NCT03263572 · RECRUITING

Trial details

NCT number: NCT03263572
Sponsor: M.D. Anderson Cancer Center
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive Acute Lymphoblastic Leukemia BCR-ABL1 Fusion Protein Expression Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive Philadelphia Chromosome Positive Recurrent Acute Lymphoblastic Leukemia Refractory Acute Lymphoblastic Leukemia t(9;22)

Start date: 2017-11-29
Primary completion: 2027-11-30
Enrollment: 90

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.